Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
NCT00628290
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Cannabidiol
DRUG:
Amisulpride
Sponsor
University of Cologne